Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

        Market and Distribute a Tobacco Product

Substantial Equivalence

                        
                Marketing Orders for SE
          Questions and Answers on SE
          Common Issues Found in Substantial Equivalence Reports Home
          Tobacco Products
          Products, Guidance & Regulations
          Market and Distribute a Tobacco Product
          Substantial EquivalenceMarket and Distribute a Tobacco Product Substantial Equivalence
  	
        Share
    Post
    Linkedin

    Email
    Print**On this page:**

Overview of Substantial Equivalence (SE)
	Preparing an SE Report
	SE Review Process
	SE Decisions
	SE ResourcesOverview of SE

A Substantial Equivalence (SE) Report can be submitted by any manufacturer for any new tobacco product seeking an FDA substantially equivalent order, under section 905(j) of the Federal Food, Drug, and Cosmetic (FD&C) Act. A substantially equivalent tobacco product is one that has been found by FDA to have either the same characteristics as a predicate product or has different characteristics than the predicate tobacco product but the Substantial Equivalence Report demonstrates that the new product does not raise different questions of public health. A predicate tobacco product is one that was commercially marketed (other than for test marketing) in the United States as of Feb. 15, 2007, or is a product previously found to be substantially equivalent by FDA.

The final rule: Content and Format of Substantial Equivalence Reports; Food and Drug Administration Actions on Substantial Equivalence Reports describes the required content, format and review of Substantial Equivalence Reports. For FDA to complete a substantive review, an SE Report must include the information described in the final rule.

**Note**: **New tobacco products commercially marketed after February 15, 2007 but before March 22, 2011 with an*SE Report*submitted by March 22, 2011 are known as provisional SE tobacco products— these may continue to be marketed unless FDA issues an order that the new product is not substantially equivalent.*

Preparing an SE Report

An SE Report must meet the content requirements specified within the SE Final Rule, (per 21 CFR 1107.18(a)). The following is not meant to be an exhaustive list of all requirements for an SE Report, but rather highlights information for the new product and predicate product commonly omitted by applicants.

**An SE Report should include:**

**General information**, such as:

	Manufacturer
		Product name, including brand and sub-brand
		Product category, subcategory, and associated product properties
	**Summary** including descriptions of similarities and differences between the new tobacco product and the predicate tobacco product with respect to their characteristics (materials, ingredients, design, composition, heating source, or other features)
	**New tobacco product description**
	**Predicate tobacco product description** 
	**Eligible predicate tobacco products** have either been: 
		**Commercially marketed** (other than for test marketing) in the United States as of February 15, 2007; or
			**Previously determined to be substantially equivalent** by FDA
		A **predicate tobacco product** must also be:
		**An individual product** and not a composite of multiple products
			**Not subject of a rescission** action by FDA
			**Not removed from the market** at the initiative of FDA
			**Not misbranded or adulterated** as determined by judicial order
	**Comparison** information
	Comparison of **product design**
		Comparison of **heating sources**
		Comparison of **product composition**
		Materials
			Ingredients other than tobacco
			Tobacco ingredients
			Container closure system
		Comparison of tobacco **processing**
		**Shelf life and stability** information
	Comparative testing information, which must include the**test protocols, quantitative acceptance criteria, and test results** (including means and variances and complete data sets)
	**Statement of compliance** with applicable tobacco product standards
	**Health information summary** or statement that such information will be made available upon request
	**Environmental assessment** prepared in accordance with 21 CFR 25.40 or a valid claim of categorical exclusion
	**Certification statement**SE Reports must also meet applicable required items per the final rule Refuse to Accept Procedures for Premarket Tobacco Submissions.

**SE format requirements** must be met to facilitate review. The application must:

**Use appropriate FDA submission forms**

	FDA 3964 – Tobacco Substantial Equivalence Report Amendment and General Correspondence Submission [PDF 2.37 MB]
		FDA 3965 – Tobacco Substantial Equivalence Report Submission [PDF 1.27 MB]
	Include a **comprehensive index** (listing of files and associated metadata)
	Include a **table of contents**
	Be **well-organized, legible, and written in English**
	Be **submitted in an electronic format** that FDA can process, read, review, and archive, unless FDA has granted a waiver 
	Applicants who cannot meet the requirement to submit their SE Report in an electronic format that FDA can process, read, review, and archive must request and receive a waiver from FDA to submit in another format.
		Waivers will be granted if use of electronic means is not reasonable for the applicant.**How to Submit an SE Report**

Request an Industry Account Manager (IAM) account to establish a CTP Portal account, if your company does not already have an IAM.
	Prepare your submission electronically using FDA's eSubmitter software and the eSubmitter template “CTP Transmittal Form.”
	Submit online via the CTP Portal.**N****ote**: *The CTP Portal provides more functionality than the ESG, and CTP recommends using the CTP Portal. However, if you already have an ESG WebTrader account, you may use it to submit documents to CTP.***Amendments** should be submitted using the above instructions. Any amendment must include, among other things, the appropriate form and specify the submission tracking number(s) of the amended SE Report in the subject line.

**Deficiency responses (including requests)** should follow the submission instructions outlined in the deficiency letter.

SE Review Process

Exemption from Substantial Equivalence
**Acceptance of an SE Report for Review:**An administrative review that ensures the product falls under Center for Tobacco Products jurisdiction and confirms that the statutory and regulatory requirements of an application are met based upon sections 910and 905(j) of the FD&C Act and the criteria set forth in §§ 1105.10 and 1107.18.

	Output
		Acceptance letter or
			Refuse to accept (RTA) letter
	Notification: FDA evaluation to ensure the predicate tobacco product is eligible.  
	Output
		None required.
			The Office of Compliance and Enforcement (OCE) may reach out to the applicant for clarifying information to support predicate eligibility.
			**For provisional SE Reports only*: A notification letter informing that review of predicate eligibility has started, substantive scientific review will occur within 181 days, and that the applicant may amend their SE Report with any additional information within 180 days.
	Substantive Review: FDA evaluation of the scientific information and data in an application.
	Output
		Deficiency letter: Additional information is needed to make a substantial equivalence decision. Applicants are provided time to respond as noted within this letter.
			Environmental information request letter: FDA made a scientific decision to support a marketing order; however, the applicant is required to provide information for environmental considerations before a marketing order can be issued.
			**For certain product quantity SE Reports:* Predicate Advice letter: FDA made a scientific decision to support a marketing order if the predicate is found eligible; however, FDA cannot issue a marketing order because it has not taken action on a different SE Report for a new product that is serving as the predicate product in the current SE Report.
	Action:
	Output
		Substantial equivalence order (SE order) letter or
			Not substantially equivalent order (NSE order) letterSE Decisions

SE Orders
	Marketed Tobacco Products that Receive an NSE
	Provisional SE Products Removed from Review
	Tobacco Product Marketing OrdersSE Resources

Rule
	Content and Format of Substantial Equivalence Reports; Food and Drug Administration Actions on Substantial Equivalence Reports
	Guidance
	Section 905(j) Reports- Demonstrating Substantial Equivalence for Tobacco Products
		Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions
	Reference Tools
	Guidance: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies
		SE Report Appendices: Common Issues
		2021 Deemed Product Review: A Conversation with the Center for Tobacco Products Office of Science
		2019 Deemed Tobacco Product Applications Public Meeting
		2018 Tobacco Product Application Review Public Meeting
		Scientific Policy Memoranda about FDA Review
		Refuse to Accept Procedures for Premarket Tobacco Product Submissions
		National Environmental Policy Act; Environmental Assessments for Tobacco Products
		Establishing that a Tobacco Product was Commercially Marketed in the United States as of February 15, 2007
		Submit and Reference Tobacco Product Master Files (TPMF)
		Scientific Policy Memoranda about FDA Review
		Tobacco Compliance Webinars for Manufacturers

                                                                                  Content current as of:
      05/03/2022
                  
                   
Regulated Product(s)
		 TobaccoSubstantial Equivalence                
                          

                        Marketing Orders for SE
          Questions and Answers on SE
          Common Issues Found in Substantial Equivalence Reports
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop